# High-risk early HR-positive breast cancer

Source: https://onco.cc/cancers/hr-positive-early-high-risk/  
OnCo record `hr-positive-early-high-risk` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy.

## Summary

High-risk early disease is defined clinically and genomically. monarchE took node-positive tumours with four or more nodes, or one to three nodes with grade 3, a tumour of 5 cm or more or Ki-67 of 20 percent or more; NATALEE widened the net to stage II and III disease including node-negative stage IIA tumours with high-risk features. Genomic assays sort the rest: TAILORx showed that women over 50 with node-negative tumours and an Oncotype DX recurrence score of 11 to 25 gain nothing from chemotherapy (nine-year invasive disease-free survival 83.3 percent without and 84.3 percent with), RxPONDER showed the same for postmenopausal women with one to three positive nodes and a score up to 25 while premenopausal women still benefited, and MINDACT showed that clinically high-risk tumours with a low MammaPrint score reach 94.7 percent five-year distant metastasis-free survival without chemotherapy.

Endocrine therapy is the backbone. Five years of tamoxifen cuts recurrence and breast cancer death for at least fifteen years, aromatase inhibitors do slightly better in postmenopausal women, and the SOFT and TEXT trials showed that premenopausal women at higher risk do best with ovarian function suppression plus exemestane, with twelve-year disease-free survival of 80.5 percent against 75.9 percent for suppression plus tamoxifen; adding suppression to tamoxifen improved overall survival in the women who had needed chemotherapy. ATLAS and aTTom showed that ten years of tamoxifen beats five, and MA.17 that letrozole after five years of tamoxifen reduces late recurrence, so extended therapy to seven to ten years is offered in node-positive disease at the price of bone loss, joint pain and adherence that falls with every year.

The CDK4/6 inhibitors changed the adjuvant standard. monarchE randomised 5,637 women to two years of abemaciclib with endocrine therapy or endocrine therapy alone and cut invasive recurrence (hazard ratio 0.68), with the gap still widening at five years; NATALEE randomised 5,101 to three years of ribociclib with an aromatase inhibitor (hazard ratio 0.75) and won approval in September 2024. Palbociclib failed twice in the same setting (PALLAS, PENELOPE-B), a reminder that the class does not behave as one drug. Adjuvant olaparib for a year adds survival for germline BRCA carriers (OlympiA), adjuvant giredestrant improved invasive disease-free survival in lidERA in 2025, camizestrant switching is being tested in CAMBRIA, and circulating tumour DNA is being studied to find the women whose late relapse is coming.

## Fields

- Kind: Cancer
- Last checked: 2026-09-17
- Also known as: High-risk early hormone receptor-positive, HER2-negative breast cancer; Node-positive luminal breast cancer; Stage II to III HR-positive breast cancer
- Tags: subtype-page
- Group: breast
- Burden: Hormone receptor-positive, HER2-negative tumours are about seven in ten breast cancers and most are cured; the high-risk minority with node involvement, large size or high grade account for most of the relapses, which in this subtype can arrive ten or twenty years after diagnosis.
- Subtypes: Luminal A-like, node-positive disease (genomic assay decides chemotherapy); Luminal B-like disease with high grade or high Ki-67 (chemotherapy and CDK4/6 inhibitor candidates); Node-positive disease with four or more nodes (monarchE population); Stage II node-negative disease with high-risk features (NATALEE population); Premenopausal disease (ovarian function suppression, SOFT and TEXT); Late recurrence risk beyond five years (extended endocrine therapy)
- Biomarkers: Oestrogen and progesterone receptor percentage; HER2-negative status (HER2-low noted for later lines); Tumour grade and Ki-67; Nodal stage and tumour size (monarchE and NATALEE eligibility); Oncotype DX recurrence score (TAILORx, RxPONDER); MammaPrint 70-gene risk (MINDACT); Menopausal status and oestradiol during ovarian suppression; Germline BRCA1 and BRCA2 (OlympiA eligibility)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/hr-positive-early-high-risk/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/hr-positive-early-high-risk/#overview [4 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/hr-positive-early-high-risk/#what-it-is [6 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/hr-positive-early-high-risk/#finding-it [8 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/hr-positive-early-high-risk/#treating-it [6 settings, 6 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/hr-positive-early-high-risk/#evidence [18 trials, 4 key papers, 10 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/hr-positive-early-high-risk/#science [5 targets]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/hr-positive-early-high-risk/where-you-are/ [16 UK centres]
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/hr-positive-early-high-risk/#living-with-it [24 questions, 6 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/hr-positive-early-high-risk/coming/ [14 medicines, 16 trials, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/hr-positive-early-high-risk/data/ [72 connected records]

## Standard of care

- Deciding on chemotherapy: Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score. ([Oncotype DX](https://onco.cc/drugs/oncotype-dx/), [MammaPrint (70-gene signature)](https://onco.cc/drugs/mammaprint/), [TAILORx](https://onco.cc/trials/tailorx/), [RxPONDER (SWOG S1007)](https://onco.cc/trials/rxponder/), [MINDACT](https://onco.cc/trials/mindact/))
- Endocrine therapy: Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease. ([Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Exemestane](https://onco.cc/drugs/exemestane/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/), [SOFT & TEXT](https://onco.cc/trials/soft-text/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/))
- Adjuvant CDK4/6 inhibitor: Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor. ([Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [monarchE](https://onco.cc/trials/monarche/), [NATALEE](https://onco.cc/trials/natalee/), [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/))
- Germline BRCA carriers: One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA). ([Olaparib](https://onco.cc/drugs/olaparib/), [OlympiA](https://onco.cc/trials/olympia/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/))
- Local therapy: Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved. ([Lumpectomy (breast-conserving surgery)](https://onco.cc/terms/lumpectomy/), [Mastectomy](https://onco.cc/terms/mastectomy/), [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/))
- Bone protection: Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence. ([Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/), [Denosumab](https://onco.cc/drugs/denosumab/))

## State of the art

- Two adjuvant CDK4/6 inhibitors, abemaciclib and ribociclib, are approved for high-risk disease on the strength of trials of more than five thousand women each.
- Genomic assays have moved most node-negative and many node-positive postmenopausal women off chemotherapy without loss of cure.
- Ovarian suppression with an aromatase inhibitor is the standard for higher-risk premenopausal women, and the POSITIVE study showed endocrine therapy can be paused safely to attempt pregnancy.
- Oral oestrogen receptor degraders are entering the adjuvant setting after lidERA.

## Open problems

- No test yet identifies the women whose relapse will come after ten years, when endocrine therapy has stopped.
- Two to three years of a CDK4/6 inhibitor is costly and its overall survival benefit is not yet proven.
- Adherence to endocrine therapy falls to about half by five years because of joint pain, hot flushes and sexual side effects.
- Premenopausal women with node-positive disease still gain from chemotherapy in RxPONDER, and whether ovarian suppression could replace it is unanswered.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Breast_cancer
- TAILORx (NEJM 2018): https://doi.org/10.1056/NEJMoa1804710
- monarchE (JCO 2020): https://doi.org/10.1200/JCO.20.02514
- NATALEE (NEJM 2024): https://doi.org/10.1056/NEJMoa2305488
- Wikipedia: https://en.wikipedia.org/wiki/Breast_cancer

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [HR-positive metastatic breast cancer after CDK4/6 inhibitors](https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/)
- trials: [(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer](https://onco.cc/trials/nct05607004/), [A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer](https://onco.cc/trials/nct07043725/), [A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer](https://onco.cc/trials/nct07349069/), [A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer](https://onco.cc/trials/nct07287098/), [CAMBRIA-1 & CAMBRIA-2](https://onco.cc/trials/cambria/), [Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer](https://onco.cc/trials/nct05780567/), [lidERA](https://onco.cc/trials/lidera/), [MINDACT](https://onco.cc/trials/mindact/), [monarchE](https://onco.cc/trials/monarche/), [NATALEE](https://onco.cc/trials/natalee/), [OlympiA](https://onco.cc/trials/olympia/), [PALLAS & PENELOPE-B](https://onco.cc/trials/pallas-penelope-b/), [PENELOPE-B](https://onco.cc/trials/penelope-b/), [RxPONDER (SWOG S1007)](https://onco.cc/trials/rxponder/), [SOFT & TEXT](https://onco.cc/trials/soft-text/), [Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)](https://onco.cc/trials/nct03725059/), [TAILORx](https://onco.cc/trials/tailorx/), [To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer](https://onco.cc/trials/nct06389006/)
- key papers: [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/), [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer](https://onco.cc/key-papers/paper-tailorx-nejm-2018/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [ArteraAI Breast](https://onco.cc/drugs/artera-ai-breast/), [Camizestrant](https://onco.cc/drugs/camizestrant/), [Denosumab](https://onco.cc/drugs/denosumab/), [Exemestane](https://onco.cc/drugs/exemestane/), [Giredestrant](https://onco.cc/drugs/giredestrant/), [Goserelin / leuprolide (ovarian function suppression)](https://onco.cc/drugs/goserelin/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [MammaPrint (70-gene signature)](https://onco.cc/drugs/mammaprint/), [Olaparib](https://onco.cc/drugs/olaparib/), [Oncotype DX](https://onco.cc/drugs/oncotype-dx/), [Ribociclib](https://onco.cc/drugs/ribociclib/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [Hypofractionated radiotherapy](https://onco.cc/technologies/hypofractionated-radiotherapy/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Sentinel lymph node biopsy](https://onco.cc/technologies/sentinel-node/)
- terms: [Lumpectomy (breast-conserving surgery)](https://onco.cc/terms/lumpectomy/), [Mastectomy](https://onco.cc/terms/mastectomy/)
- biomarkers: [ER status (oestrogen receptor by IHC)](https://onco.cc/biomarkers/er-status/), [Ki-67 index (proliferation by IHC)](https://onco.cc/biomarkers/ki-67-index/)

---
JSON: https://onco.cc/api/v1/entities/hr-positive-early-high-risk.json